Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults

The Advisory Committee on Immunization Practices (ACIP) recommends recombinant zoster vaccine (RZV) to prevent against herpes zoster (HZ) and related complications in immunocompetent adults ≥50 y and immunocompromised adults ≥19 y. In 2019, a statistical safety signal for Guillain-Barré syndrome (GB...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2022-11, Vol.18 (5), p.2060668-2060668
Main Authors: Janusz, Cara B, Anderson, Tara C, Leidner, Andrew J, Lee, Grace M, Dooling, Kathleen, Prosser, Lisa A
Format: Article
Language:English
Subjects:
Adult
adult vaccination
Aged
Brief Report
Cost-Benefit Analysis
Herpes Zoster - epidemiology
Herpes Zoster - prevention & control
herpes zoster vaccination
Herpes Zoster Vaccine
Herpesvirus 3, Human
Humans
Licensed Vaccines – Short Report
Medicare
recombinant zoster vaccine
risk-benefit
shingrix
United States - epidemiology
vaccine safety
Vaccines, Synthetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The Advisory Committee on Immunization Practices (ACIP) recommends recombinant zoster vaccine (RZV) to prevent against herpes zoster (HZ) and related complications in immunocompetent adults ≥50 y and immunocompromised adults ≥19 y. In 2019, a statistical safety signal for Guillain-Barré syndrome (GBS) following RZV was identified using data from the Vaccine Safety Datalink (VSD). Subsequently, the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and collaborators undertook additional analyses using Centers for Medicare & Medicaid Services (CMS) Medicare data to further investigate the potential risk of GBS following RZV. Concurrently, epidemiologic data suggested a potentially elevated risk of GBS following HZ in U.S. adults. Using data from these sources and a published simulation model, this study evaluated the health benefits and risks associated with vaccinating immunocompetent adults ≥50 y with RZV compared to no vaccination. In the base case analysis, RZV vaccination averted 43,000-63,000 cases of HZ, including GBS complications, per million vaccinated per 10-y age cohort compared to 3-6 additional cases of GBS projected following RZV per million vaccinated in the same population. This analysis highlights the projected health benefits of RZV vaccination compared to the relatively low potential risk of GBS following RZV.
ISSN:2164-5515
2164-554X
DOI:10.1080/21645515.2022.2060668